Skip to main content
Erschienen in: Clinical Reviews in Allergy & Immunology 1/2018

29.11.2017

Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

verfasst von: Marianne Lerch, Carlo Mainetti, Benedetta Terziroli Beretta-Piccoli, Thomas Harr

Erschienen in: Clinical Reviews in Allergy & Immunology | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are considered a delayed-type hypersensitivity reaction to drugs. They represent true medical emergencies and an early recognition and appropriate management is decisive for the survival. SJS/TEN manifest with an “influenza-like” prodromal phase (malaise, fever), followed by painful cutaneous and mucous membrane (ocular, oral, and genital) lesions, and other systemic symptoms. The difference between SJS, SJS/TEN overlap, and TEN is defined by the degree of skin detachment: SJS is defined as skin involvement of < 10%, TEN is defined as skin involvement of > 30%, and SJS/TEN overlap as 10–30% skin involvement. The diagnosis of different degrees of epidermal necrolysis is based on the clinical assessment in conjunction with the corresponding histopathology. The mortality rates for SJS and TEN have decreased in the last decades. Today, the severity-of-illness score for toxic epidermal necrolysis (SCORTEN) is available for SJS/TEN severity assessment. Drugs with a high risk of causing SJS/TEN are anti-infective sulfonamides, anti-epileptic drugs, non-steroidal anti-inflammatory drugs of the oxicam type, allopurinol, nevirapine, and chlormezanone. Besides conventional drugs, herbal remedies and new biologicals should be considered as causative agents. The increased risk of hypersensitivity reactions to certain drugs may be linked to specific HLA antigens. Our understanding of the pathogenesis of SJS/TEN has improved: drug-specific T cell-mediated cytotoxicity, genetic linkage with HLA- and non-HLA-genes, TCR restriction, and cytotoxicity mechanisms were clarified. However, many factors contributing to epidermal necrolysis still have to be identified, especially in virus-induced and autoimmune forms of epidermal necrolysis not related to drugs. In SJS/TEN, the most common complications are ocular, cutaneous, or renal. Nasopharyngeal, esophageal, and genital mucosal involvement with blisters, erosions as well as secondary development of strictures also play a role. However, in the acute phase, septicemia is a leading cause of morbidity and fatality. Pulmonary and hepatic involvement is frequent. The acute management of SJS/TEN requires a multidisciplinary approach. Immediate withdrawal of potentially causative drugs is mandatory. Prompt referral to an appropriate medical center for specific supportive treatment is of utmost importance. The most frequently used treatments for SJS/TEN are systemic corticosteroids, immunoglobulins, and cyclosporine A.
Literatur
1.
Zurück zum Zitat Stevens A, Johnson F (1922) A new eruptive fever associated with stomatitis and ophtalmia; report on two cases in children. Am J Dis Child 24:526–533CrossRef Stevens A, Johnson F (1922) A new eruptive fever associated with stomatitis and ophtalmia; report on two cases in children. Am J Dis Child 24:526–533CrossRef
2.
Zurück zum Zitat Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68(11):355–361PubMedCrossRef Lyell A (1956) Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 68(11):355–361PubMedCrossRef
3.
Zurück zum Zitat Fiessinger R, Rendu R (1917) Sur un syndrome charactérisé par l'inflammation simultanée de toutes les muqueuses externes coexistant avec une éruption vésiculeuse des quatre membres, non douloureuse et non recidivante. Paris Méd 25:54–58 Fiessinger R, Rendu R (1917) Sur un syndrome charactérisé par l'inflammation simultanée de toutes les muqueuses externes coexistant avec une éruption vésiculeuse des quatre membres, non douloureuse et non recidivante. Paris Méd 25:54–58
4.
Zurück zum Zitat Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129(1):92–96PubMedCrossRef Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC (1993) Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 129(1):92–96PubMedCrossRef
5.
Zurück zum Zitat Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138(8):1019–1024PubMedCrossRef Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC (2002) Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 138(8):1019–1024PubMedCrossRef
6.
7.
Zurück zum Zitat Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM (1990) The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126(1):43–47PubMedCrossRef Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, Walker AM (1990) The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 126(1):43–47PubMedCrossRef
10.
Zurück zum Zitat Sakamoto AP, Silva CA, Saad-Magalhaes C, Alencar AN, Pereira RM, Kozu K, Barbosa CM, Terreri MT (2017) Stevens-Johnson syndrome and toxic epidermal necrolysis in childhood-onset systemic lupus erythematosus patients: a multicenter study. Acta Reumatol Port 42(3):250–255 Sakamoto AP, Silva CA, Saad-Magalhaes C, Alencar AN, Pereira RM, Kozu K, Barbosa CM, Terreri MT (2017) Stevens-Johnson syndrome and toxic epidermal necrolysis in childhood-onset systemic lupus erythematosus patients: a multicenter study. Acta Reumatol Port 42(3):250–255
13.
Zurück zum Zitat Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 49(7):769–773PubMedCrossRef Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, Hollander N, Bruppacher R, Schopf E (1996) Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990–1992): structure and results of a population-based registry. J Clin Epidemiol 49(7):769–773PubMedCrossRef
14.
Zurück zum Zitat Diphoorn J, Cazzaniga S, Gamba C, Schroeder J, Citterio A, Rivolta AL, Vighi GD, Naldi L (2016) Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf 25(2):196–203. https://doi.org/10.1002/pds.3937 PubMedCrossRef Diphoorn J, Cazzaniga S, Gamba C, Schroeder J, Citterio A, Rivolta AL, Vighi GD, Naldi L (2016) Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf 25(2):196–203. https://​doi.​org/​10.​1002/​pds.​3937 PubMedCrossRef
23.
Zurück zum Zitat Cote B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC (1995) Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 131(11):1268–1272PubMedCrossRef Cote B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC (1995) Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 131(11):1268–1272PubMedCrossRef
24.
Zurück zum Zitat Roujeau JC (1997) Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 24(11):726–729PubMedCrossRef Roujeau JC (1997) Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 24(11):726–729PubMedCrossRef
25.
Zurück zum Zitat Rzany B, Hering O, Mockenhaupt M, Schroder W, Goerttler E, Ring J, Schopf E (1996) Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 135(1):6–11PubMedCrossRef Rzany B, Hering O, Mockenhaupt M, Schroder W, Goerttler E, Ring J, Schopf E (1996) Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 135(1):6–11PubMedCrossRef
30.
Zurück zum Zitat Prieto-Barrios M, Velasco-Tamariz V, Tous-Romero F, Burillo-Martinez S, Zarco-Olivo C, Rodriguez-Peralto JL, Ortiz-Romero PL (2017) Linear immunoglobulin A dermatosis mimicking toxic epidermal necrolysis: a case report of etanercept treatment. Br J Dermatol. https://doi.org/10.1111/bjd.15400 Prieto-Barrios M, Velasco-Tamariz V, Tous-Romero F, Burillo-Martinez S, Zarco-Olivo C, Rodriguez-Peralto JL, Ortiz-Romero PL (2017) Linear immunoglobulin A dermatosis mimicking toxic epidermal necrolysis: a case report of etanercept treatment. Br J Dermatol. https://​doi.​org/​10.​1111/​bjd.​15400
32.
Zurück zum Zitat Chanal J, Ingen-Housz-Oro S, Ortonne N, Duong TA, Thomas M, Valeyrie-Allanore L, Lebrun-Vignes B, Andre C, Roujeau JC, Chosidow O, Wolkenstein P (2013) Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol 169(5):1041–1048. https://doi.org/10.1111/bjd.12488 PubMedCrossRef Chanal J, Ingen-Housz-Oro S, Ortonne N, Duong TA, Thomas M, Valeyrie-Allanore L, Lebrun-Vignes B, Andre C, Roujeau JC, Chosidow O, Wolkenstein P (2013) Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. Br J Dermatol 169(5):1041–1048. https://​doi.​org/​10.​1111/​bjd.​12488 PubMedCrossRef
44.
Zurück zum Zitat Correia O, Delgado L, Barbosa IL, Domingues JC, Azevedo R, Vaz CP, Pimentel P (2001) CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: further similarities with toxic epidermal necrolysis. Dermatology 203(3):212–216PubMedCrossRef Correia O, Delgado L, Barbosa IL, Domingues JC, Azevedo R, Vaz CP, Pimentel P (2001) CD8+ lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: further similarities with toxic epidermal necrolysis. Dermatology 203(3):212–216PubMedCrossRef
46.
Zurück zum Zitat Villada G, Roujeau JC, Cordonnier C, Bagot M, Kuentz M, Wechsler J, Vernant JP (1990) Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 23(5 Pt 1):870–875PubMedCrossRef Villada G, Roujeau JC, Cordonnier C, Bagot M, Kuentz M, Wechsler J, Vernant JP (1990) Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 23(5 Pt 1):870–875PubMedCrossRef
48.
Zurück zum Zitat Melish ME, Glasgow LA, Turner MD (1972) The staphylococcal scalded-skin syndrome: isolation and partial characterization of the exfoliative toxin. J Infect Dis 125(2):129–140PubMedCrossRef Melish ME, Glasgow LA, Turner MD (1972) The staphylococcal scalded-skin syndrome: isolation and partial characterization of the exfoliative toxin. J Infect Dis 125(2):129–140PubMedCrossRef
49.
53.
Zurück zum Zitat Alniemi DT, Wetter DA, Bridges AG, El-Azhary RA, Davis MD, Camilleri MJ, McEvoy MT (2017) Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996–2013. Int J Dermatol 56(4):405–414. https://doi.org/10.1111/ijd.13434 PubMedCrossRef Alniemi DT, Wetter DA, Bridges AG, El-Azhary RA, Davis MD, Camilleri MJ, McEvoy MT (2017) Acute generalized exanthematous pustulosis: clinical characteristics, etiologic associations, treatments, and outcomes in a series of 28 patients at Mayo Clinic, 1996–2013. Int J Dermatol 56(4):405–414. https://​doi.​org/​10.​1111/​ijd.​13434 PubMedCrossRef
54.
Zurück zum Zitat Pierard-Franchimont C, Lesuisse M, Humbert P, Delvenne P, Pierard GE (2012) Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf 7(5):357–360PubMedCrossRef Pierard-Franchimont C, Lesuisse M, Humbert P, Delvenne P, Pierard GE (2012) Toxic epidermal necrolysis and antifolate drugs in cancer chemotherapy. Curr Drug Saf 7(5):357–360PubMedCrossRef
58.
Zurück zum Zitat Samhaber KT, Bertsch HP, Schon MP, Haenssle HA (2017) In vivo reflectance confocal microscopy of erythema multiforme and Stevens-Johnson syndrome: a histopathological correlation based on a case series. J Ger Soc Dermatol 15(5):573–576. https://doi.org/10.1111/ddg.12975 Samhaber KT, Bertsch HP, Schon MP, Haenssle HA (2017) In vivo reflectance confocal microscopy of erythema multiforme and Stevens-Johnson syndrome: a histopathological correlation based on a case series. J Ger Soc Dermatol 15(5):573–576. https://​doi.​org/​10.​1111/​ddg.​12975
60.
Zurück zum Zitat Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, Mozingo DW, Yowler CJ, Sheridan RL, Ahrenholz DH, Caruso DM, Foster KN, Kagan RJ, Voigt DW, Purdue GF, Hunt JL, Wolf S, Molitor F (2002) A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23(2):87–96PubMedCrossRef Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, Mozingo DW, Yowler CJ, Sheridan RL, Ahrenholz DH, Caruso DM, Foster KN, Kagan RJ, Voigt DW, Purdue GF, Hunt JL, Wolf S, Molitor F (2002) A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil 23(2):87–96PubMedCrossRef
68.
Zurück zum Zitat Bansal S, Garg VK, Sardana K, Sarkar R (2015) A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of toxic epidermal necrolysis. Int J Dermatol 54(1):e18–e26. https://doi.org/10.1111/ijd.12466 PubMedCrossRef Bansal S, Garg VK, Sardana K, Sarkar R (2015) A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORe of toxic epidermal necrolysis. Int J Dermatol 54(1):e18–e26. https://​doi.​org/​10.​1111/​ijd.​12466 PubMedCrossRef
73.
Zurück zum Zitat Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88(1):60–68. https://doi.org/10.1038/clpt.2009.252 PubMedCrossRef Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H (2010) ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther 88(1):60–68. https://​doi.​org/​10.​1038/​clpt.​2009.​252 PubMedCrossRef
74.
Zurück zum Zitat Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14(12):1343–1350. https://doi.org/10.1038/nm.1884 Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT (2008) Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med 14(12):1343–1350. https://​doi.​org/​10.​1038/​nm.​1884
75.
Zurück zum Zitat Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H (2009) Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 151(7):514–515PubMedCrossRef Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H (2009) Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med 151(7):514–515PubMedCrossRef
79.
Zurück zum Zitat Yang Y, Li F, Du J, Shen Y, Lin J, Zhu X, Luo X, Liang J, Xu J (2016) Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. https://doi.org/10.1111/ajd.12462 Yang Y, Li F, Du J, Shen Y, Lin J, Zhu X, Luo X, Liang J, Xu J (2016) Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. https://​doi.​org/​10.​1111/​ajd.​12462
80.
Zurück zum Zitat Quaglino P, Caproni M, Antiga E, Del Bianco E, Osella-Abate S, Savoia P, Frezzolini A, Schena D, Marzano A, Volpi W, De Simone C, Parodi A, Fabbri P, Bernengo MG (2007) Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology. Dermatology 214(4):296–304. https://doi.org/10.1159/000100880 PubMedCrossRef Quaglino P, Caproni M, Antiga E, Del Bianco E, Osella-Abate S, Savoia P, Frezzolini A, Schena D, Marzano A, Volpi W, De Simone C, Parodi A, Fabbri P, Bernengo MG (2007) Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology. Dermatology 214(4):296–304. https://​doi.​org/​10.​1159/​000100880 PubMedCrossRef
82.
Zurück zum Zitat Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH (2017) Interleukin-15 Is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol 137(5):1065–1073. https://doi.org/10.1016/j.jid.2016.11.034 Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH (2017) Interleukin-15 Is associated with severity and mortality in Stevens-Johnson syndrome/toxic epidermal necrolysis. J Invest Dermatol 137(5):1065–1073. https://​doi.​org/​10.​1016/​j.​jid.​2016.​11.​034
84.
Zurück zum Zitat Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L, Revuz J, Roujeau JC (1996) Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35(4):234–236PubMedCrossRef Wolkenstein P, Chosidow O, Flechet ML, Robbiola O, Paul M, Dume L, Revuz J, Roujeau JC (1996) Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 35(4):234–236PubMedCrossRef
85.
Zurück zum Zitat Balachandran C, Shenoi SD, Sarkar D, Ravikumar BC (2002) Patch tests in adverse cutaneous drug reaction. Indian J Dermatol Venereol Leprol 68(1):13–15PubMed Balachandran C, Shenoi SD, Sarkar D, Ravikumar BC (2002) Patch tests in adverse cutaneous drug reaction. Indian J Dermatol Venereol Leprol 68(1):13–15PubMed
86.
Zurück zum Zitat Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J (2013) A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 168(3):555–562. https://doi.org/10.1111/bjd.12125 PubMedCrossRef Barbaud A, Collet E, Milpied B, Assier H, Staumont D, Avenel-Audran M, Grange A, Amarger S, Girardin P, Guinnepain MT, Truchetet F, Lasek A, Waton J (2013) A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. Br J Dermatol 168(3):555–562. https://​doi.​org/​10.​1111/​bjd.​12125 PubMedCrossRef
91.
Zurück zum Zitat Karami Z, Mesdaghi M, Karimzadeh P, Mansouri M, Taghdiri MM, Kayhanidoost Z, Jebelli B, Shekarriz Foumani R, Babaie D, Chavoshzadeh Z (2016) Evaluation of lymphocyte transformation test results in patients with delayed hypersensitivity reactions following the use of anticonvulsant drugs. Int Arch Allergy Immunol 170(3):158–162. https://doi.org/10.1159/000448284 PubMedCrossRef Karami Z, Mesdaghi M, Karimzadeh P, Mansouri M, Taghdiri MM, Kayhanidoost Z, Jebelli B, Shekarriz Foumani R, Babaie D, Chavoshzadeh Z (2016) Evaluation of lymphocyte transformation test results in patients with delayed hypersensitivity reactions following the use of anticonvulsant drugs. Int Arch Allergy Immunol 170(3):158–162. https://​doi.​org/​10.​1159/​000448284 PubMedCrossRef
97.
Zurück zum Zitat Klaewsongkram J, Thantiworasit P, Suthumchai N, Rerknimitr P, Sukasem C, Tuchinda P, Chularojanamontri L, Srinoulprasert Y, Rerkpattanapipat T, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Tovanabutra N, Srisuttiyakorn C (2016) In vitro test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactions. Br J Dermatol 175(5):994–1002. https://doi.org/10.1111/bjd.14701 PubMedCrossRef Klaewsongkram J, Thantiworasit P, Suthumchai N, Rerknimitr P, Sukasem C, Tuchinda P, Chularojanamontri L, Srinoulprasert Y, Rerkpattanapipat T, Chanprapaph K, Disphanurat W, Chakkavittumrong P, Tovanabutra N, Srisuttiyakorn C (2016) In vitro test to confirm diagnosis of allopurinol-induced severe cutaneous adverse reactions. Br J Dermatol 175(5):994–1002. https://​doi.​org/​10.​1111/​bjd.​14701 PubMedCrossRef
99.
Zurück zum Zitat Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128(1):35–44. https://doi.org/10.1038/sj.jid.5701033 PubMedCrossRef Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A (2008) Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 128(1):35–44. https://​doi.​org/​10.​1038/​sj.​jid.​5701033 PubMedCrossRef
103.
Zurück zum Zitat Maggio N, Firer M, Zaid H, Bederovsky Y, Aboukaoud M, Gandelman-Marton R, Noyman I, Ekstein D, Blatt I, Marom E, Schwartzberg E, Israel S, Ingber A, Brautbar C, Eyal S (2017) Causative drugs of Stevens-Johnson syndrome and toxic epidermal necrolysis in Israel. J Clin Pharmacol 57(7):823–829. https://doi.org/10.1002/jcph.873 PubMedCrossRef Maggio N, Firer M, Zaid H, Bederovsky Y, Aboukaoud M, Gandelman-Marton R, Noyman I, Ekstein D, Blatt I, Marom E, Schwartzberg E, Israel S, Ingber A, Brautbar C, Eyal S (2017) Causative drugs of Stevens-Johnson syndrome and toxic epidermal necrolysis in Israel. J Clin Pharmacol 57(7):823–829. https://​doi.​org/​10.​1002/​jcph.​873 PubMedCrossRef
117.
Zurück zum Zitat Khor AH, Lim KS, Tan CT, Kwan Z, Tan WC, Wu DB, Ng CC (2017) HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population. Pharmacogenet Genomics 27(7):275–278. https://doi.org/10.1097/fpc.0000000000000287 Khor AH, Lim KS, Tan CT, Kwan Z, Tan WC, Wu DB, Ng CC (2017) HLA-A*31: 01 and HLA-B*15:02 association with Stevens-Johnson syndrome and toxic epidermal necrolysis to carbamazepine in a multiethnic Malaysian population. Pharmacogenet Genomics 27(7):275–278. https://​doi.​org/​10.​1097/​fpc.​0000000000000287​
121.
Zurück zum Zitat Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R (2010) HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51(12):2461–2465. https://doi.org/10.1111/j.1528-1167.2010.02766.x PubMedCrossRef Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R (2010) HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Epilepsia 51(12):2461–2465. https://​doi.​org/​10.​1111/​j.​1528-1167.​2010.​02766.​x PubMedCrossRef
122.
Zurück zum Zitat Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R (2008) HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11):1617–1622. https://doi.org/10.2217/14622416.9.11.1617 PubMedCrossRef Kaniwa N, Saito Y, Aihara M, Matsunaga K, Tohkin M, Kurose K, Sawada J, Furuya H, Takahashi Y, Muramatsu M, Kinoshita S, Abe M, Ikeda H, Kashiwagi M, Song Y, Ueta M, Sotozono C, Ikezawa Z, Hasegawa R (2008) HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11):1617–1622. https://​doi.​org/​10.​2217/​14622416.​9.​11.​1617 PubMedCrossRef
123.
Zurück zum Zitat Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18(2):99–107. https://doi.org/10.1097/FPC.0b013e3282f3ef9c PubMedCrossRef Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M (2008) A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 18(2):99–107. https://​doi.​org/​10.​1097/​FPC.​0b013e3282f3ef9c​ PubMedCrossRef
125.
Zurück zum Zitat Ramirez E, Bellon T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Moreno Hidalgo MA, Castaner JL, Cabanas R, Fiandor A, Gonzalez-Ramos J, Herranz P, Cachafeiro L, Gonzalez-Herrada C, Gonzalez O, Aramburu JA, Laosa O, Hernandez R, Carcas AJ, Frias J (2017) Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res 115:168–178. https://doi.org/10.1016/j.phrs.2016.11.027 PubMedCrossRef Ramirez E, Bellon T, Tong HY, Borobia AM, de Abajo FJ, Lerma V, Moreno Hidalgo MA, Castaner JL, Cabanas R, Fiandor A, Gonzalez-Ramos J, Herranz P, Cachafeiro L, Gonzalez-Herrada C, Gonzalez O, Aramburu JA, Laosa O, Hernandez R, Carcas AJ, Frias J (2017) Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. Pharmacol Res 115:168–178. https://​doi.​org/​10.​1016/​j.​phrs.​2016.​11.​027 PubMedCrossRef
129.
Zurück zum Zitat Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, Sukasem C, Hsu CN, Su SC, Chang WC, Hui RC, Chu CY, Chen YJ, Wu CY, Hsu CK, Chiu TM, Sun PL, Lee HE, Yang CY, Kao PH, Yang CH, Ho HC, Lin JY, Chang YC, Chen MJ, CW L, Ng CY, Kuo KL, Lin CY, Yang CS, Chen DP, Chang PY, Wu TL, Lin YJ, Weng YC, Kuo TT, Hung SI, Chung WH (2017) Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 88(1):78–86. https://doi.org/10.1212/wnl.0000000000003453 PubMedCrossRef Chen CB, Hsiao YH, Wu T, Hsih MS, Tassaneeyakul W, Jorns TP, Sukasem C, Hsu CN, Su SC, Chang WC, Hui RC, Chu CY, Chen YJ, Wu CY, Hsu CK, Chiu TM, Sun PL, Lee HE, Yang CY, Kao PH, Yang CH, Ho HC, Lin JY, Chang YC, Chen MJ, CW L, Ng CY, Kuo KL, Lin CY, Yang CS, Chen DP, Chang PY, Wu TL, Lin YJ, Weng YC, Kuo TT, Hung SI, Chung WH (2017) Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. Neurology 88(1):78–86. https://​doi.​org/​10.​1212/​wnl.​0000000000003453​ PubMedCrossRef
131.
Zurück zum Zitat Tassaneeyakul W, Prabmeechai N, Sukasem C, Kongpan T, Konyoung P, Chumworathayi P, Tiamkao S, Khunarkornsiri U, Kulkantrakorn K, Saksit N, Nakkam N, Satapornpong P, Vannaprasaht S, Sangviroon A, Mahasirimongkol S, Wichukchinda N, Rerkpattanapipat T, Tassaneeyakul W (2016) Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics 26(5):225–234. https://doi.org/10.1097/fpc.0000000000000211 PubMedCrossRef Tassaneeyakul W, Prabmeechai N, Sukasem C, Kongpan T, Konyoung P, Chumworathayi P, Tiamkao S, Khunarkornsiri U, Kulkantrakorn K, Saksit N, Nakkam N, Satapornpong P, Vannaprasaht S, Sangviroon A, Mahasirimongkol S, Wichukchinda N, Rerkpattanapipat T, Tassaneeyakul W (2016) Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics 26(5):225–234. https://​doi.​org/​10.​1097/​fpc.​0000000000000211​ PubMedCrossRef
132.
Zurück zum Zitat Shi YW, Min FL, Zhou D, Qin B, Wang J, FY H, Cheung YK, Zhou JH, Hu XS, Zhou JQ, Zhou LM, Zheng ZZ, Pan J, He N, Liu ZS, Hou YQ, Lim KS, Ou YM, Hui-Ping Khor A, Ng CC, Mao BJ, Liu XR, Li BM, Kuan YY, Yi YH, He XL, Deng XY, Su T, Kwan P, Liao WP (2017) HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology 88(23):2183–2191. https://doi.org/10.1212/wnl.0000000000004008 Shi YW, Min FL, Zhou D, Qin B, Wang J, FY H, Cheung YK, Zhou JH, Hu XS, Zhou JQ, Zhou LM, Zheng ZZ, Pan J, He N, Liu ZS, Hou YQ, Lim KS, Ou YM, Hui-Ping Khor A, Ng CC, Mao BJ, Liu XR, Li BM, Kuan YY, Yi YH, He XL, Deng XY, Su T, Kwan P, Liao WP (2017) HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. Neurology 88(23):2183–2191. https://​doi.​org/​10.​1212/​wnl.​0000000000004008​
133.
Zurück zum Zitat Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102(11):4134–4139. https://doi.org/10.1073/pnas.0409500102 Hung SI, Chung WH, Liou LB, Chu CC, Lin M, Huang HP, Lin YL, Lan JL, Yang LC, Hong HS, Chen MJ, Lai PC, Wu MS, Chu CY, Wang KH, Chen CH, Fann CS, Wu JY, Chen YT (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc Natl Acad Sci U S A 102(11):4134–4139. https://​doi.​org/​10.​1073/​pnas.​0409500102
134.
Zurück zum Zitat Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W (2009) Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19(9):704–709. https://doi.org/10.1097/FPC.0b013e328330a3b8 PubMedCrossRef Tassaneeyakul W, Jantararoungtong T, Chen P, Lin PY, Tiamkao S, Khunarkornsiri U, Chucherd P, Konyoung P, Vannaprasaht S, Choonhakarn C, Pisuttimarn P, Sangviroon A, Tassaneeyakul W (2009) Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population. Pharmacogenet Genomics 19(9):704–709. https://​doi.​org/​10.​1097/​FPC.​0b013e328330a3b8​ PubMedCrossRef
136.
Zurück zum Zitat Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, Wang YL, Wu CC, Hsu CN (2017) Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol 44(6):835–843. https://doi.org/10.3899/jrheum.151476 Ke CH, Chung WH, Wen YH, Huang YB, Chuang HY, Tain YL, Wang YL, Wu CC, Hsu CN (2017) Cost-effectiveness analysis for genotyping before allopurinol treatment to prevent severe cutaneous adverse drug reactions. J Rheumatol 44(6):835–843. https://​doi.​org/​10.​3899/​jrheum.​151476
140.
Zurück zum Zitat Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, Kidkeukarun R, Preechakul S, Khunarkornsiri U, Bamrungram W, Supharatwattanakun B, Mootsikapun P, Kwangsukstid S, Denjanta S, Vannaprasaht S, Rungapiromnan W, Suwankesawong W, Tassaneeyakul W, Tassaneeyakul W (2015) Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics 25(8):402–411. https://doi.org/10.1097/fpc.0000000000000153 PubMedCrossRef Kongpan T, Mahasirimongkol S, Konyoung P, Kanjanawart S, Chumworathayi P, Wichukchinda N, Kidkeukarun R, Preechakul S, Khunarkornsiri U, Bamrungram W, Supharatwattanakun B, Mootsikapun P, Kwangsukstid S, Denjanta S, Vannaprasaht S, Rungapiromnan W, Suwankesawong W, Tassaneeyakul W, Tassaneeyakul W (2015) Candidate HLA genes for prediction of co-trimoxazole-induced severe cutaneous reactions. Pharmacogenet Genomics 25(8):402–411. https://​doi.​org/​10.​1097/​fpc.​0000000000000153​ PubMedCrossRef
141.
Zurück zum Zitat Ueta M, Sawai H, Shingaki R, Kawai Y, Sotozono C, Kojima K, Yoon KC, Kim MK, Seo KY, Joo CK, Nagasaki M, Kinoshita S, Tokunaga K (2017) Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. J Hum Genet 62(4):485–489. https://doi.org/10.1038/jhg.2016.160 PubMedCrossRef Ueta M, Sawai H, Shingaki R, Kawai Y, Sotozono C, Kojima K, Yoon KC, Kim MK, Seo KY, Joo CK, Nagasaki M, Kinoshita S, Tokunaga K (2017) Genome-wide association study using the ethnicity-specific Japonica array: identification of new susceptibility loci for cold medicine-related Stevens-Johnson syndrome with severe ocular complications. J Hum Genet 62(4):485–489. https://​doi.​org/​10.​1038/​jhg.​2016.​160 PubMedCrossRef
142.
Zurück zum Zitat Ciccacci C, Latini A, Politi C, Mancinelli S, Marazzi MC, Novelli G, Palombi L, Borgiani P (2017) Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-017-2295-2 Ciccacci C, Latini A, Politi C, Mancinelli S, Marazzi MC, Novelli G, Palombi L, Borgiani P (2017) Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. Eur J Clin Pharmacol. https://​doi.​org/​10.​1007/​s00228-017-2295-2
143.
Zurück zum Zitat Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, Roujeau JC (2000) Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 119(1):225–230PubMedPubMedCentralCrossRef Le Cleach L, Delaire S, Boumsell L, Bagot M, Bourgault-Villada I, Bensussan A, Roujeau JC (2000) Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 119(1):225–230PubMedPubMedCentralCrossRef
145.
Zurück zum Zitat Correia O, Delgado L, Roujeau JC, Le Cleach L, Fleming-Torrinha JA (2002) Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 138(1):29–32PubMedCrossRef Correia O, Delgado L, Roujeau JC, Le Cleach L, Fleming-Torrinha JA (2002) Soluble interleukin 2 receptor and interleukin 1alpha in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 138(1):29–32PubMedCrossRef
149.
Zurück zum Zitat Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, Roques S, Friedmann PS, Contassot E, French LE (2013) TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 133(2):489–498. https://doi.org/10.1038/jid.2012.330 PubMedCrossRef Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, Roques S, Friedmann PS, Contassot E, French LE (2013) TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol 133(2):489–498. https://​doi.​org/​10.​1038/​jid.​2012.​330 PubMedCrossRef
151.
Zurück zum Zitat Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, Alvarez J, Romano A, Juarez C, Blanca M (2002) Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 109(1):155–161PubMedCrossRef Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, Alvarez J, Romano A, Juarez C, Blanca M (2002) Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol 109(1):155–161PubMedCrossRef
152.
Zurück zum Zitat Inachi S, Mizutani H, Shimizu M (1997) Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol 133(7):845–849PubMedCrossRef Inachi S, Mizutani H, Shimizu M (1997) Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol 133(7):845–849PubMedCrossRef
160.
161.
Zurück zum Zitat Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC (2013) Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133(5):1197–1204. https://doi.org/10.1038/jid.2012.510 PubMedCrossRef Sekula P, Dunant A, Mockenhaupt M, Naldi L, Bouwes Bavinck JN, Halevy S, Kardaun S, Sidoroff A, Liss Y, Schumacher M, Roujeau JC (2013) Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Invest Dermatol 133(5):1197–1204. https://​doi.​org/​10.​1038/​jid.​2012.​510 PubMedCrossRef
165.
Zurück zum Zitat McGee T, Munster A (1998) Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 102(4):1018–1022PubMedCrossRef McGee T, Munster A (1998) Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 102(4):1018–1022PubMedCrossRef
169.
Zurück zum Zitat Pinheiro S, Carvalho R, Ramos S, Diogo C, Caetano M, Cabral L, Cruzeiro C (2013) Toxic epidermal necrolysis: the experience of Coimbra’s burn unit. Acta Medica Port 26(4):341–348 Pinheiro S, Carvalho R, Ramos S, Diogo C, Caetano M, Cabral L, Cruzeiro C (2013) Toxic epidermal necrolysis: the experience of Coimbra’s burn unit. Acta Medica Port 26(4):341–348
170.
171.
Zurück zum Zitat Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, Roupie E, Revuz J, Roujeau JC (1997) Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 23(12):1237–1244PubMedCrossRef Lebargy F, Wolkenstein P, Gisselbrecht M, Lange F, Fleury-Feith J, Delclaux C, Roupie E, Revuz J, Roujeau JC (1997) Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 23(12):1237–1244PubMedCrossRef
172.
Zurück zum Zitat Duong TA, de Prost N, Ingen-Housz-Oro S, Carrie AS, Zerah F, Valeyrie-Allanore L, Bagot M, Chosidow O, Roujeau JC, Wolkenstein P, Maitre B (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. Br J Dermatol 172(2):400–405. https://doi.org/10.1111/bjd.13505 PubMedCrossRef Duong TA, de Prost N, Ingen-Housz-Oro S, Carrie AS, Zerah F, Valeyrie-Allanore L, Bagot M, Chosidow O, Roujeau JC, Wolkenstein P, Maitre B (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. Br J Dermatol 172(2):400–405. https://​doi.​org/​10.​1111/​bjd.​13505 PubMedCrossRef
176.
Zurück zum Zitat Belafsky PC, Postma GN, Koufman JA, Bach KK (2002) Stevens-Johnson syndrome with diffuse esophageal involvement. Ear Nose Throat J 81(4):220PubMed Belafsky PC, Postma GN, Koufman JA, Bach KK (2002) Stevens-Johnson syndrome with diffuse esophageal involvement. Ear Nose Throat J 81(4):220PubMed
177.
Zurück zum Zitat Mahe A, Keita S, Blanc L, Bobin P (1993) Esophageal necrosis in the Stevens-Johnson syndrome. J Am Acad Dermatol 29(1):103–104PubMedCrossRef Mahe A, Keita S, Blanc L, Bobin P (1993) Esophageal necrosis in the Stevens-Johnson syndrome. J Am Acad Dermatol 29(1):103–104PubMedCrossRef
178.
Zurück zum Zitat Njei B, Schoenfeld A, Vaziri H (2013) Esophageal stricture secondary to drug-induced toxic epidermal necrolysis presenting in an adult: an unusual complication of a rare disease. Conn Med 77(9):541–544PubMed Njei B, Schoenfeld A, Vaziri H (2013) Esophageal stricture secondary to drug-induced toxic epidermal necrolysis presenting in an adult: an unusual complication of a rare disease. Conn Med 77(9):541–544PubMed
179.
Zurück zum Zitat Misra SP, Dwivedi M, Misra V (2004) Esophageal stricture as a late sequel of Stevens-Johnson syndrome in adults: incidental detection because of foreign body impaction. Gastrointest Endosc 59(3):437–440PubMedCrossRef Misra SP, Dwivedi M, Misra V (2004) Esophageal stricture as a late sequel of Stevens-Johnson syndrome in adults: incidental detection because of foreign body impaction. Gastrointest Endosc 59(3):437–440PubMedCrossRef
180.
Zurück zum Zitat Carter FM, Mitchell CK (1993) Toxic epidermal necrolysis—an unusual cause of colonic perforation. Report of a case. Dis Colon Rectum 36(8):773–777PubMedCrossRef Carter FM, Mitchell CK (1993) Toxic epidermal necrolysis—an unusual cause of colonic perforation. Report of a case. Dis Colon Rectum 36(8):773–777PubMedCrossRef
182.
Zurück zum Zitat Meneux E, Wolkenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ (1998) Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 91(2):283–287PubMedCrossRef Meneux E, Wolkenstein P, Haddad B, Roujeau JC, Revuz J, Paniel BJ (1998) Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 91(2):283–287PubMedCrossRef
187.
Zurück zum Zitat Morelli MS, O'Brien FX (2001) Stevens-Johnson syndrome and cholestatic hepatitis. Dig Dis Sci 46(11):2385–2388PubMedCrossRef Morelli MS, O'Brien FX (2001) Stevens-Johnson syndrome and cholestatic hepatitis. Dig Dis Sci 46(11):2385–2388PubMedCrossRef
188.
Zurück zum Zitat Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, Reddy V, Patil M (2016) Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases. Hepatology 63(3):993–999. https://doi.org/10.1002/hep.28270 PubMedCrossRef Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, Reddy V, Patil M (2016) Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases. Hepatology 63(3):993–999. https://​doi.​org/​10.​1002/​hep.​28270 PubMedCrossRef
190.
Zurück zum Zitat Srivastava M, Perez-Atayde A, Jonas MM (1998) Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 115(3):743–746PubMedCrossRef Srivastava M, Perez-Atayde A, Jonas MM (1998) Drug-associated acute-onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology 115(3):743–746PubMedCrossRef
192.
Zurück zum Zitat Okan G, Yaylaci S, Peker O, Kaymakoglu S, Saruc M (2008) Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol 14(29):4697–4700PubMedPubMedCentralCrossRef Okan G, Yaylaci S, Peker O, Kaymakoglu S, Saruc M (2008) Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol 14(29):4697–4700PubMedPubMedCentralCrossRef
193.
Zurück zum Zitat Harimoto N, Wang H, Ikegami T, Takeishi K, Itoh S, Yamashita YI, Yoshizumi T, Aishima S, Shirabe K, Oda Y, Maehara Y (2015) Education and Imaging. Hepatology: rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation. J Gastroenterol Hepatol 30(4):656. https://doi.org/10.1111/jgh.12849 PubMedCrossRef Harimoto N, Wang H, Ikegami T, Takeishi K, Itoh S, Yamashita YI, Yoshizumi T, Aishima S, Shirabe K, Oda Y, Maehara Y (2015) Education and Imaging. Hepatology: rare Stevens-Johnson syndrome and vanishing bile duct syndrome induced by acetaminophen, requiring liver transplantation. J Gastroenterol Hepatol 30(4):656. https://​doi.​org/​10.​1111/​jgh.​12849 PubMedCrossRef
195.
Zurück zum Zitat Garcia M, Mhanna MJ, Chung-Park MJ, Davis PH, Srivastava MD (2002) Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes. Dig Dis Sci 47(1):177–182PubMedCrossRef Garcia M, Mhanna MJ, Chung-Park MJ, Davis PH, Srivastava MD (2002) Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes. Dig Dis Sci 47(1):177–182PubMedCrossRef
199.
Zurück zum Zitat Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, Iijima M, Aihara M, Ikezawa Z, Aihara Y, Kano Y, Shiohara T, Tohyama M, Shirakata Y, Kaneda H, Fukushima M, Kinoshita S, Hashimoto K (2015) Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 160(2):228–237.e222. https://doi.org/10.1016/j.ajo.2015.05.002 PubMedCrossRef Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, Iijima M, Aihara M, Ikezawa Z, Aihara Y, Kano Y, Shiohara T, Tohyama M, Shirakata Y, Kaneda H, Fukushima M, Kinoshita S, Hashimoto K (2015) Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol 160(2):228–237.e222. https://​doi.​org/​10.​1016/​j.​ajo.​2015.​05.​002 PubMedCrossRef
211.
Zurück zum Zitat Kavanagh GM, Page P, Hanna MM (1994) Silicone gel treatment of extensive hypertrophic scarring following toxic epidermal necrolysis. Br J Dermatol 130(4):540–541PubMedCrossRef Kavanagh GM, Page P, Hanna MM (1994) Silicone gel treatment of extensive hypertrophic scarring following toxic epidermal necrolysis. Br J Dermatol 130(4):540–541PubMedCrossRef
216.
Zurück zum Zitat Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC (2000) Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 136(3):323–327PubMedCrossRef Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC (2000) Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 136(3):323–327PubMedCrossRef
221.
Zurück zum Zitat Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, Finkelstein Y, Burnett M, Sade S, Cartotto R, Jeschke M, Shear NH (2016) Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 175(2):422–424. https://doi.org/10.1111/bjd.14799 PubMedCrossRef Dodiuk-Gad RP, Olteanu C, Feinstein A, Hashimoto R, Alhusayen R, Whyte-Croasdaile S, Finkelstein Y, Burnett M, Sade S, Cartotto R, Jeschke M, Shear NH (2016) Major psychological complications and decreased health-related quality of life among survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 175(2):422–424. https://​doi.​org/​10.​1111/​bjd.​14799 PubMedCrossRef
224.
Zurück zum Zitat Tripathi A, Ditto AM, Grammer LC, Greenberger PA, McGrath KG, Zeiss CR, Patterson R (2000) Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 21(2):101–105PubMedCrossRef Tripathi A, Ditto AM, Grammer LC, Greenberger PA, McGrath KG, Zeiss CR, Patterson R (2000) Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc 21(2):101–105PubMedCrossRef
225.
Zurück zum Zitat Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC (2012) The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol 167(3):555–562. https://doi.org/10.1111/j.1365-2133.2012.11074.x PubMedCrossRef Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC (2012) The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. Br J Dermatol 167(3):555–562. https://​doi.​org/​10.​1111/​j.​1365-2133.​2012.​11074.​x PubMedCrossRef
231.
Zurück zum Zitat Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282(5388):490–493PubMedCrossRef Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282(5388):490–493PubMedCrossRef
232.
Zurück zum Zitat Prins C, Vittorio C, Padilla RS, Hunziker T, Itin P, Forster J, Brocker EB, Saurat JH, French LE (2003) Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 207(1):96–99PubMedCrossRef Prins C, Vittorio C, Padilla RS, Hunziker T, Itin P, Forster J, Brocker EB, Saurat JH, French LE (2003) Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 207(1):96–99PubMedCrossRef
233.
Zurück zum Zitat Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139(1):26–32PubMedCrossRef Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE (2003) Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 139(1):26–32PubMedCrossRef
234.
Zurück zum Zitat Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 139(1):39–43PubMedCrossRef Trent JT, Kirsner RS, Romanelli P, Kerdel FA (2003) Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami experience. Arch Dermatol 139(1):39–43PubMedCrossRef
236.
Zurück zum Zitat Huang YC, Chien YN, Chen YT, Li YC, Chen TJ (2016) Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. G Ital Dermatol Venereol 151(5):515–524PubMed Huang YC, Chien YN, Chen YT, Li YC, Chen TJ (2016) Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: a systematic review and meta-analysis. G Ital Dermatol Venereol 151(5):515–524PubMed
237.
Zurück zum Zitat Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, Kurien G (2013) Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol 79(4):506–511. https://doi.org/10.4103/0378-6323.113080 PubMedCrossRef Jagadeesan S, Sobhanakumari K, Sadanandan SM, Ravindran S, Divakaran MV, Skaria L, Kurien G (2013) Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases. Indian J Dermatol Venereol Leprol 79(4):506–511. https://​doi.​org/​10.​4103/​0378-6323.​113080 PubMedCrossRef
238.
Zurück zum Zitat Aires DJ, Fraga G, Korentager R, Richie CP, Aggarwal S, Wick J, Liu DY (2013) Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol 12(6):679–684PubMed Aires DJ, Fraga G, Korentager R, Richie CP, Aggarwal S, Wick J, Liu DY (2013) Early treatment with nonsucrose intravenous immunoglobulin in a burn unit reduces toxic epidermal necrolysis mortality. J Drugs Dermatol 12(6):679–684PubMed
239.
Zurück zum Zitat Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J (2000) Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48(3):473–478PubMedCrossRef Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J (2000) Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 48(3):473–478PubMedCrossRef
245.
Zurück zum Zitat Gonzalez-Herrada C, Rodriguez-Martin S, Cachafeiro L, Lerma V, Gonzalez O, Lorente JA, Rodriguez-Miguel A, Gonzalez-Ramos J, Roustan G, Ramirez E, Bellon T, de Abajo FJ (2017) Ciclosporin use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. https://doi.org/10.1016/j.jid.2017.05.022 Gonzalez-Herrada C, Rodriguez-Martin S, Cachafeiro L, Lerma V, Gonzalez O, Lorente JA, Rodriguez-Miguel A, Gonzalez-Ramos J, Roustan G, Ramirez E, Bellon T, de Abajo FJ (2017) Ciclosporin use in epidermal necrolysis is associated with an important mortality reduction: evidence from three different approaches. J Invest Dermatol. https://​doi.​org/​10.​1016/​j.​jid.​2017.​05.​022
250.
Zurück zum Zitat St John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, Ho AW, Raff AB, Sugai DY, Schalock P, Kroshinsky D (2017) Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol 34(5):540–546. https://doi.org/10.1111/pde.13236 PubMedCrossRef St John J, Ratushny V, Liu KJ, Bach DQ, Badri O, Gracey LE, Ho AW, Raff AB, Sugai DY, Schalock P, Kroshinsky D (2017) Successful use of cyclosporin A for Stevens-Johnson syndrome and toxic epidermal necrolysis in three children. Pediatr Dermatol 34(5):540–546. https://​doi.​org/​10.​1111/​pde.​13236 PubMedCrossRef
257.
Zurück zum Zitat Fischer M, Fiedler E, Marsch WC, Wohlrab J (2002) Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146(4):707–709PubMedCrossRef Fischer M, Fiedler E, Marsch WC, Wohlrab J (2002) Antitumour necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 146(4):707–709PubMedCrossRef
Metadaten
Titel
Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis
verfasst von
Marianne Lerch
Carlo Mainetti
Benedetta Terziroli Beretta-Piccoli
Thomas Harr
Publikationsdatum
29.11.2017
Verlag
Springer US
Erschienen in
Clinical Reviews in Allergy & Immunology / Ausgabe 1/2018
Print ISSN: 1080-0549
Elektronische ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-017-8654-z

Weitere Artikel der Ausgabe 1/2018

Clinical Reviews in Allergy & Immunology 1/2018 Zur Ausgabe

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.